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16444 | RSC Adv., 2018, 8, 16444–1645of nanocomposites of carbon
nanotubes and polycaprolactone with high aspect
ratios with potential applications in drug delivery†
Edyta Niezabitowska,a Jessica Smith, a Mark R. Prestly, a Riaz Akhtar,b Felix W. von
Aulock,c Yan Lavalle´e,c Hanene Ali-Boucettad and Tom O. McDonald *a
The geometries and surface properties of nanocarriers greatly inﬂuence the interaction between
nanomaterials and living cells. In this work we combine multiwalled carbon nanotubes (CNTs) with poly-
3-caprolactone (PCL) to produce non-spherical nanocomposites with high aspect ratios by using a facile
emulsion solvent evaporation method. Particles were characterised by dynamic light scattering (DLS),
scanning electron microscopy (SEM), atomic force microscopy (AFM) and asymmetric ﬂow ﬁeld ﬂow
fractionation (AF4). Diﬀerent sizes and morphologies of nanoparticles were produced depending on the
concentration of the sodium dodecyl sulphate (SDS), CNTs and PCL. Rod-like PCL-CNT nanostructures
with low polydispersity were obtained with 1.5 mg mL1 of SDS, 0.9 mg mL1 of CNTs and 10 mg mL1
PCL. AFM analysis revealed that the PCL and PCL-CNT nanocomposite had comparatively similar moduli
of 770 and 560 MPa respectively, indicating that all the CNTs have been coated with at least 2 nm of
PCL. Thermogravimetric analysis of the PCL-CNT nanocomposite indicated that they contained 9.6%
CNTs by mass. The asymmetric ﬂow ﬁeld ﬂow fractionation of the samples revealed that the PCL-CNT
had larger hydrodynamic diameters than PCL alone. Finally, the drug loading properties of the
nanocomposites were assessed using docetaxel as the active substance. The nanocomposites showed
comparable entrapment eﬃciencies of docetaxel (89%) to the CNTs alone (95%) and the PCL
nanoparticles alone (81%). This is a facile method for obtaining non-spherical nanocomposites that
combines the properties of PCL and CNTs such as the high aspect ratio, modulus. The high drug
entrapment eﬃciency of these nanocomposites may have promising applications in drug delivery.Introduction
The use of nanomaterials for applications in drug delivery has
been shown to oﬀer a wide range of potential benets such as
encapsulating both hydrophilic and hydrophobic substances,
improving the stability of drugs and providing targeted
delivery.1 These benets have been particularly well demon-
strated in the treatment of cancer where a large number of
therapies are now used clinically.2,3 However, eﬀectively max-
imising the dose of the drug at the target site versus systemic
distribution still remains a considerable challenge for any
therapy. Recently, there has been growing interest in therpool, Crown Street, Liverpool, L69 7ZD,
c.uk
nd Aerospace Engineering, School of
ow Hill, Liverpool, L69 3GH, UK
ity of Liverpool, Jane Herdman Building,
ical and Dental Sciences, University of
2TT, UK
tion (ESI) available. See DOI:
4inuence of the geometry and stiﬀness of nanomaterials on
their interaction with cells and tissues.4–11 A wide range of
geometries and structures are synthetically possible such as
nanoparticles,12–14 nanotubes,15–17 nanodisks,18 nanoshells19,20
and nanowires.21 The size, shape, stiﬀness and surface chem-
istry of nanomaterials has been shown to inuence cytotox-
icity,22 drug release,23 targeting and imaging contrast
eﬃciency.24 Generally, high aspect ratio (length/diameter)
nanomaterials can provide improved drug delivery potential
in comparison to spherical nanoparticles.4,5
Carbon nanotubes (CNTs) are a type of high aspect ratio
nanomaterial and they possess a range of interesting properties
including their nanoscale size, unique bre structure, large
surface area and high mechanical stiﬀness.15 These properties
have led to CNTs being investigated as drug delivery
systems.16,25 CNTs have shown benets in DNA delivery,26 use as
cancer theranostics,27,28 small molecule drug delivery16 and
regenerative medicine.29 CNTs can be covalently modied with
drug molecules, or they can physically adsorb aromatic drugs
via the strong p–p and hydrophobic interactions between the
drug and the aromatic surface of the CNT. Such physical
adsorption of drugs has been exploited for loadingThis journal is © The Royal Society of Chemistry 2018
Fig. 1 Scheme for the preparation of PCL-CNTs nanocomposites by
an oil-in water emulsion solvent evaporation method. The solution of
PCL and dispersion of CNTs (both in DCM) was emulsiﬁed in an
aqueous surfactant solution. The resulting emulsion was kept stirring
until the DCMhad evaporated resulting in PCL-CNTs nanocomposites.
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View Article Onlineanthracyclines, a class of anticancer drug.16 However, in spite of
their drug loading potential, the inherently hydrophobic nature
of CNTs can limit their application in aqueous environments.
As such, surface modication and coating is oen utilised to
improve the colloidal stability of CNTs.30 The cytotoxicity and
biocompatibility of CNTs has been shown to be dependent on
many factors such as the route of administration, the size and
type of the CNTs (MWNT or SWNT) and presence of any surface
modication;31,32 generally higher surface functionalisation of
CNTs reduced cytotoxicity.33 Polymers are typically used for
surface modication and these have been graed to the
surfaces of CNTs by amidation, radical coupling, esterication
and other reactions.34 Alternatively, graing from the surface of
CNTs by anionic/cationic polymerizations or atom transfer
radical polymerization has also been used.35,36 An attractive
coating for CNTs would be poly(3-caprolactone) (PCL), a poly-
mer that has been widely investigated for drug delivery12 and
a component of clinically approved devices.37 A number of
composites of CNTs and PCL have been shown with the pres-
ence of the CNTs in a matrix of PCL, however, the majority of
these are in the form of bulk polymers,38–40 electrospun
bres,41,42 lms,43–45 or foams.46 These materials have shown
promising properties for biological applications. Mattioli-
Belmonte et al. showed that high level of CNTs incorporation
(>60% weight) into a bulk PCLmatrix caused cytotoxicity and no
diﬀerence in cell viability was observed at lower CNT concen-
trations between PCL alone or the PCL-CNT composite.47
Moreover, other researchers have reported enhanced cell
proliferation when CNTs were incorporated into PCL compos-
ites prepared by electrospinning.42 It is therefore clear that the
biological response to PCL CNT composites depends on
a number of factors including the concentration of CNTs and
the morphology of the matrix material.
There are only a small number of examples of CNTs and PCL
nanocomposites in the form of nanoparticles, in which indi-
vidual CNTs are coated in PCL.36,48 Additionally, these nano-
particulate nanocomposites are prepared by chemical
attachment of the polymer to the surface of the CNT and the
resulting high-aspect ratio nanostructure were only dispersible
in organic solvents. An alternative approach is to modify the
CNTs by non-covalent functionalisation. This approach is
particularly attractive due to the relative simplicity of process
and the fact that it introduces fewer defects to the graphitic
structure of the CNTs.49 A few examples of this approach have
been shown, these include coating of the CNTs with poly(-
ethylene glycol)-phospholipid conjugates,50 forming
a biopolymer coating using layer-by-layer assembly,51 or stabil-
ising the surface with Pluronic F-127, a commercially available
surfactant.52 The chemical structure of adsorbed polymer has
been shown to inuence the cytotoxicity and oxidative stress
caused by the CNTs, and in the case, adverse biological eﬀects
were seen at a concentration of CNTs of 50 mg mL1.53 One issue
with non-covalent modication of CNTs is that the forces
between the coating and the CNT are typically weak and
desorption may occur especially in vivo.54 To overcome this
issue, we are hypothesising that the use of the oil-in-water
emulsion solvent evaporation method with CNTs will enableThis journal is © The Royal Society of Chemistry 2018the preparation of CNTs with a physically attached coating of
solid PCL that would not be easily desorbed. It is well reported
that water-dispersible PCL nanoparticles can be prepared by the
facile oil-in-water emulsion solvent evaporation method. In this
process the polymer solution is emulsied and nanoparticles
are formed upon evaporation of the solvent for the polymer.55
Additionally, PCL nanoparticles can provide entrapment eﬃ-
ciencies exceeding 80% and drug loadings of up to 20%.56 The
potential of combining CNTs with their high modulus with the
improved drug loading with PCL, a medically-proven polymer,
may provide unique nanomaterials with promising biomedical
applications.
In this study, we demonstrate a facile approach to produce
high-aspect ratio nanocomposites comprising of CNTs and
PCL, with the aim of combining the benets of both materials
and encapsulating the anti-cancer drug docetaxel. We investi-
gate the formation of nanocomposites by an oil-in-water
emulsion solvent evaporation route (Fig. 1) and examine how
to control the size and morphology of the particles. The nano-
composite composition and novel morphology of the particles
are characterised by DLS, SEM, AFM, TGA and AF4. Finally, we
investigate the potential for loading the nanocomposites with
docetaxel and monitor the in vitro drug release.Experimental
Materials
Polycaprolactone (PCL, molecular weight 14 000 g mol1),
sodium dodecyl sulphate (SDS), ammonium nitrate were
purchased from Sigma-Aldrich. Non-functionalised multiwalled
carbon nanotubes (MWCNTs) were purchased from Nano-
structured & Amorphous Materials Inc. (Houston, USA) at 95%
purity (Stock no. 1237YJS). According to the manufacturer,RSC Adv., 2018, 8, 16444–16454 | 16445
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View Article OnlineMWCNTs have an outside diameter 20–30 nm and length
ranging between 0.5 and 2 mm. Docetaxel was purchased from
Chemleader Biomedical. Dichloromethane (DCM) (analytical
reagent grade), acetone, acetonitrile (HPLC grade) were
purchased from AgraNova. Milli-Q water obtained from a water
purication system had a resistivity of >18 MU cm1 (PURELAB
option R, Veolia). 10 kDa dialysis membrane was purchased
from Spectrum Labs.
Synthesis of PCL-CNTs
Nanocomposites of PCL and CNTs were prepared by an oil-in-
water emulsion solvent evaporation method. CNTs were
dispersed in 1 mL of DCM to form a dispersion with a concen-
tration of 0.5 mg mL1. The dispersion of CNTs was sonicated
for 30 s using a Hielscher UP400 s ultrasonic processor (400
watts, 24 kHz, 45% of amplitude, 1 cycle). Next, the specic
amount of PCL was dissolved in DCM (total volume 1 mL) to
form the organic phase. The aqueous phase was prepared by
dissolution of SDS in 4 mL of distilled water. The two organic
phases were transferred into 14 mL glass vials containing the
aqueous phase, dropwise through a needle (21G). In the next
step, the immiscible phases were homogenised for 30 s using
a Hielscher UP400s ultrasonic processor (400 watts, 24 kHz,
45% of amplitude, 1 cycle) to obtain an emulsion. The nano-
dispersion was mixed by magnetic stirring (500 rpm, hotplate
model: Stuart US152D) overnight (16 h) to allow evaporation
of DCM.
Encapsulation of docetaxel into PCL-CNTs nanocomposites
PCL-CNTs nanocomposites with encapsulated docetaxel were
prepared by an oil-in-water emulsion solvent evaporation
method as previously described in the synthesis of PCL-CNTs
method. CNTs were dispersed in 1 mL of DCM to form
a dispersion with a concentration of 0.5 mg mL1. Next, the
specic amount of PCL was dissolved in DCM (total volume 1
mL) to form the organic phase. Docetaxel (DCX) was dissolved
in 1 mL of acetone. The aqueous phase was prepared by dis-
solving SDS in 4 mL of distilled water. The three organic phases
were transferred into 14 mL glass vials containing the water
phase, dropwise through a needle (21G). In the next step, the
immiscible solution was homogenised for 30 s using
a Hielscher UP400s ultrasonic processor (45% of amplitude, 1
cycle) to obtain an emulsion. The nanosuspension wasmixed by
magnetic stirring (500 rpm) overnight 16 h to allow the DCM
to evaporate. The same method was used to obtain PCL and
CNTs alone.
Characterisation
A Hitachi S-4800 cold Field emission (FE-SEM) scanning elec-
tron microscope (SEM) was used to image PCL NPs and PCL-
CNTs. The samples to be analysed were centrifuged at
9000 rpm for 1 hours and washed with deionised water three
times prior to addition (concentration 1 mg mL1) to glass
coverslips stuck onto an aluminium stubs using carbon double-
sided sticky tabs from Agar Scientic, Essex, UK and le to
evaporate overnight. The prepared samples were coated with16446 | RSC Adv., 2018, 8, 16444–16454gold for 2.5 minutes at 20 mA using an EMITECH K550X Sputter
Coater.
Asymmetric ow eld ow fractionation experiments were
performed on an MT2000 with RI and UV-vis detectors from
Postnova Analytics, Landsberg/Germany. The sizes of the
samples were obtained by dynamic light scattering (DLS) using
a Malvern Zetasizer Nano ZS (running Malvern Zetasizer so-
ware V7.11) (Malvern Instruments, Malvern, UK) with 633 nm
He–Ne laser and the detector positioned at 173, coupled online
to the MT2000. A 350 mm spacer and 10 kDa regenerative
cellulose (RC) membrane were installed in the separation
channel. The conditions used for the separations was based on
a method existing in the literature.57 Briey, The mobile phase
was 1  105 mol L1 NH4NO3 in Milli-Q H2O. Type I distilled
water was obtained from a water purication system had
a resistivity of >18 MU cm1 (PURELAB option R, Veolia). The
injected volume was 30 mL of 1 mg mL1 sample. The injection/
focussing time was 5 min using a cross ow of 2 mL min1. The
cross ow rate was 2 mL min1 for the rst 15 min (t0–t15) in
constant manner, and thereaer, the cross ow was linearly
decreased from its initial value to 0 over a period of 5 min.
Following the complete reduction in cross ow, the tip-ow
continued for an additional 35 min. The UV-vis detector
measured wavelength were monitored for 300 nm. The Z-
average diameter and count rate were measured by an inline
Malvern Zetasizer ZS DLS at 3 second intervals. DLS calculates
the Z-average size of particles using the Stokes–Einstein
equation.
AFM measurements of the samples were performed with the
samples deposited on glass coverslips which were adhered to
mica substrates. The samples were prepared on the glass
coverslip stuck onto mica substrates. A few microliters of sus-
pended sample (concentration1 mgmL1) were pipetted onto
the mica surface and le to dry by exposing to air overnight
(16 h). AFM imaging was conducted using a Bruker Multi-
mode 8 instrument (Bruker, Santa Barbara, USA), operated in
ambient conditions with a Bruker RTESPA-525 probe using the
Peakforce Quantitative Nanomechanical Mapping (PFQNM)
method.58,59 The RTESPA-525 probe has a nominal spring
constant of 200 N m1 and a tip radius of 8 nm. All scans were
conducted at a scan rate of 0.576 Hz with a scan size of 2.00
mm.58
Thermo-gravimetric analyses (TGA) were performed in
a simultaneous thermal analyser (STA) 449F1 Jupiter (Netzsch
GmbH), which includes a thermo-gravimetric analyser. Samples
of unprocessed CNTs, PCL nanoparticles and the PCL-CNT
nanocomposites (5–15 mg) were added to platinum pan. In
the case of the PCL nanoparticles and the PCL-CNT nano-
composites, these dispersions were prepared using the usual
method and were then freeze-dried prior to addition of the dry
powder to the analysis pans. The atmosphere of the samples,
the pan and the sample holder were evacuated and purged with
argon three times to remove the air before analysis. The
samples were then analysed by heating at a heating rate of
10 C min1 to 700 C in an atmosphere of argon owing at 20
mL min1, whilst monitoring weight changes at a resolution of
25 ng.This journal is © The Royal Society of Chemistry 2018
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View Article OnlineQuantication of docetaxel by HPLC
HPLC measurements were performed with the use of a Perki-
nElmer Series 200 instrument. The chromatographic conditions
were used as previously described in the literature.60 The chro-
matograph column used was an Agilent Zorbax Eclipse Plus
C18. Solvent A contained HPLC grade water and solvent B
consisted of HPLC grade acetonitrile. The ow rate of the
mobile phase was 1.0 mLmin1. The HPLC gradient was kept as
T/% B (T is time and B is a percentage of acetonitrile solvent): 0/
35, 15/65, 25/75, 30/95, 35/100, 39/100 and 40/35 with a post run
time of 5 min. The column was maintained at 25 C. The
detection wavelength was 230 nm. The injection volume was 10
mL. The diluent used was a 1 : 1 mixture of water and
acetonitrile.
A calibration curve was prepared for docetaxel from 14
standard solutions. Samples were prepared by dissolving the
appropriate amount of docetaxel in 1 : 1 mixture water and
acetonitrile. A linear calibration plot for the above method was
obtained over 3.9 mg mL1 to 250 mg mL1. The correlation
coeﬃcient was 0.99.
In order to calculate the encapsulation eﬃciency of the
samples the amount of ‘free’ docetaxel (i.e. not encapsulated in
the nanoparticles) was measured. Firstly, the samples loaded
with docetaxel were freeze dried for 24 h to remove the water.
Aer that, the freeze dried samples were dispersed in 2 mL of
HPLC methanol for 15 min. The methanol was then transferred
to a spin lter tube (cut oﬀ 3.5 kDa) and centrifuged at 6000 g
for 1 h at 20 C. The ltered solution was then analysed by HPLC
using the same method and column as for the drug release
study.In vitro drug release
Briey, 4 mL of PCL, CNTs and PCL-CNTs-PLGA nanoparticles
solution (1 mg mL1) were introduced into dialysis membrane
bag (12–14 kDa, Spectrum Laboratories Inc.) The end-sealed
dialysis bag was incubated into 500 mL of distilled water in
the 25 C. Every 24 h, 250 mL of water was taken and freeze
dried to remove water. Aer that, the freeze dried samples were
dispersed in 2 mL of 1 : 1 mixture water and acetonitrile.
Solution was analysed by HPLC, using the same method as
described in HPLC method section. The release media was
changed every 24 h.Fig. 2 The eﬀect of changing the concentration of CNTs and SDS on
the Z-average diameter (A) and the PdI (B) of the resulting nano-
particles as measured by DLS. The concentration of PCL was 6 mg
mL1.Results and discussion
Inuence of the concentration of SDS, CNTs and PCL on
particle size and morphology
The synthesis of PCL-CNTs nanocomposites was attempted by
an oil-in water emulsion solvent evaporation method (Fig. 1),
PCL and CNTs were contained in DCM which was then emul-
sied by sonication with an aqueous phase of the surfactant
sodium dodecyl sulphate (SDS). The DCM was then le to
evaporate under ambient conditions. Two variables were
initially investigated: the concentration of SDS in the aqueous
phase and the concentration of CNTs in the oil phase, with the
concentration of PCL kept constant at 6 mg mL1. We observedThis journal is © The Royal Society of Chemistry 2018that samples containing higher concentrations of CNTs
produced a turbid emulsion which was a darker grey-black in
colour. The samples were then puried by centrifugation to
remove any excess surfactant before being analysed by DLS. The
analysis of the samples by DLS provided the mean hydrody-
namic diameters of the particles and a measure of the broad-
ness of the particle size distribution, quantied by the
polydispersity index (PdI) (Fig. 2). It was found that particles
without SDS had the largest diameters and that there was
a further increase in the size as the CNT concentration
increased from 0.03 mg mL1 to 0.9 mg mL1 of CNTs, with
a diameter ranging from 289 to 434 nm respectively (Fig. 2A).
The same eﬀect was visible for PdI results; the absence of
surfactant resulted in the highest PdI values (Fig. 2B). Without
SDS, the high interfacial tension between water and DCMwould
result in an emulsion with low stability, this will have led to
droplet coalescence upon evaporation of the DCM, giving
a higher mean particle diameter and broad particle size distri-
bution. An SDS concentration of 1.5 mg mL1 produced the
smallest particles and the lowest PdIs for all of the three CNT
concentrations. Concentrations above 1.5 mg mL1 of SDS did
not reduce particle size further suggesting 1.5 mg mL1 was
suﬃcient concentration of surfactant to minimise droplet coa-
lescence, further increases in concentration generally increased
the mean diameter or polydispersity index (Fig. 2). At the lowest
concentration of SDS tested (below 0.5 mg mL1) and a high
concentration of CNTs (above 0.6 mg mL1) particles were ob-
tained with larger mean diameters. The presence of the CNTs
which had a mean length of 425 nm (see (ESI), Fig. S1†) in the
DCM may have resulted in non-spherical droplets with a larger
apparent hydrodynamic diameter. DLS analysis generally
showed monomodal distributions for the samples (See ESI,
Fig. S2†) with the PdI ranging between 0.169 (6 mg mL1 PCL
0.03 mg mL1 CNTs and 1.5 mg mL1 SDS) and 0.428, a multi-
modal distribution (6 mg mL1 PCL, 0.9 mg mL1 CNTs and
0 mg mL1 SDS). The concentration of SDS signicantly
impacted the results. When there was SDS no present broad size
distributions were obtained, whereas when the SDS concentra-
tion was above 1.5 mg mL1 smaller particles and a narrower
distributions was obtained.
Selected samples were then further characterised by scan-
ning electron microscopy (SEM) to provide information on the
morphology and particle size in the dried state, as shown inRSC Adv., 2018, 8, 16444–16454 | 16447
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View Article OnlineFig. 3. In order to minimise charging during imaging the
samples were sputter-coated with gold. All the samples
appeared to have agglomerated upon drying. The length and
width of the particles was then determined from the SEM
images. When no SDS was used large spherical particles (392–
659 nm depending on CNTs concentration) were obtained with
diameters approximately matching those determined by DLS.
As previously mentioned, it is likely that in the absence of
surfactant the interfacial tension between the water and DCM
resulted in droplet coalescence. When the concentration of the
CNTs was increased it resulted in particles with more irregular,
less spherical morphology. At higher concentrations of SDS
(1.5 mg mL1 and 3 mg mL1) and with CNTs present, rod-like
morphologies were observed for all samples, these structures
closely resemble those previously reported in the literature for
PCL-CNT nanocomposites prepared by a covalent modication
with either a “graing from” approach36 or click chemistry
method.48 This behaviour was likely due to the SDS lowering the
interfacial tension between the DCM and the aqueous contin-
uous phase resulting in smaller emulsion drops. The CNTs will
preferentially be wet by DCM rather than water due to the
hydrophobic nature of CNTs.61 As the diameter of a DCM
droplet approaches the length of the CNT dispersed within the
droplet there is the potential for the CNT to be exposed to the
surrounding aqueous continuous phase as the DCM evaporates.
Minimisation of the interfacial energy of the system will lead to
the DCM–water interface growing rather than create new CNT–
water interface. This behaviour would likely result in a non-
spherical droplet being formed. It can then be expected thatFig. 3 SEM images of the nanomaterials showing the inﬂuence of SDS
and CNT concentration on the diﬀerent sizes and morphologies of the
nanocomposites of PCL/CNTs. (a) 6 mgmL1 of PCL, 0.03 mgmL1 of
CNTs and 0 mg mL1 SDS (b) 6 mg mL1 of PCL, 0.03 mg mL1 of
CNTs and 1.5 mg mL1 of SDS (c) 6 mg mL1 of PCL, 0.03 mg mL1 of
CNTs and 3 mg mL1 of SDS (d) 6 mg mL1 of PCL, 0.3 mg mL1 of
CNTs and 0 mg mL1 of SDS (e) 6 mg mL1 of PCL, 0.3 mg mL1 of
CNTs and 1.5 mgmL1 of SDS (f) 6 mgmL1 of PCL, 0.3 mgmL1 CNTs
and 3mgmL1 of SDS (g) 6 mgmL1 of PCL, 0.9 mgmL1 of CNTs and
0 mg mL1 of SDS (h) 6 mg mL1 of PCL, 0.9 mg mL1 of CNTs and
1.5 mg mL1 of SDS (i) 6 mg mL1 of PCL, 0.9 mg mL1 of CNTs and
3 mg mL1 of SDS. All samples were dispersed in 4 mL of distilled
water. Scale bar applies to all images.
16448 | RSC Adv., 2018, 8, 16444–16454as the DCM continued to evaporate the PCL would be deposited
onto the surface of the CNT. These experiments suggest that the
presence of the surfactant would have allowed smaller droplets
of DCM containing the PCL and CNTs to form, upon evapora-
tion of the DCM non-spherical nanomaterials were then formed
(see Fig. 4 for a visual representation of this hypothesis).
The PCL-CNT nanocomposites displayed colloidal stability
in water for at least 5 days with very little change in the mean
diameter and polydispersity over that time period (see ESI,
Fig. S3†). In phosphate buﬀered saline, a common mimic for
physiological uids, the nanocomposites showed colloidal
instability as the ions in the salt screened out the electrostatic
stabilisation of the particles (see ESI, Fig. S4†). We believe that
this issue can be address in the future by the use of a polymer
stabiliser that will provide steric stabilisation to the nano-
composites. The reproducibility of synthesis of the PCL-CNT
samples was also tested, three selected samples were repro-
duced, in these the concentration of PCL used 3 mg mL1 and
with diﬀering concentrations of CNTs (0.01–0.3 mg mL1) and
SDS (0–1 mg mL1). In each case the standard deviations of the
replicates were found to be less than 10% of the mean diameterFig. 4 Cartoon representation of how the surfactant concentration
during the emulsiﬁcation process inﬂuences the morphology of the
nanocomposites.
This journal is © The Royal Society of Chemistry 2018
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View Article Onlineof the sample (see ESI, Fig. S5†). This nding showed that the
oil-in water emulsion solvent evaporation method is a robust
and reliable process for obtaining non-spherical nanomaterials.
From the range of concentrations that were tested, a single
formulation was selected for each type of nanodispersion: PCL
alone nanoparticles, a CNT alone dispersion and a PCL-CNT
nanocomposite (see Table 1). These samples were then
prepared for further analysis and comparison between the
properties of the diﬀerent nanostructures.
The morphology and properties of the sample as studied by
AFM SEM and TGA
SEM and AFM characterisation was then conducted to further
investigate the surface, morphology and mechanical properties
of the PCL-CNT nanocomposite; this was compared to PCL
nanoparticles and CNTs alone (Fig. 5). The same regions of each
sample was imaged by both SEM and AFM, however, it was not
possible to image precisely the same location with both tech-
niques. In the preparation of these samples no gold coating was
used for the SEM as this would invalidate the mechanical
characterisation of the sample by AFM analysis. Therefore, in
order to prevent surface charging the SEM was operated in
deceleration mode, which led to a slight reduction of the image
quality. As before, the sample of PCL alone consisted of
spherical particles with a mean diameter of 382 nm and
appeared to agglomerate upon drying (Fig. 5A). Analysis of the
sample of CNTs alone revealed bres with varying lengths (200–
795 nm with a mean length 324 nm and width 53 nm) (Fig. 5B),
a similar morphology was observed for the nanocomposite
sample containing both PCL and CNT (Fig. 5C) where the
sample consisted of high aspect ratio bres with a mean width
of 55 nm and mean length of 172 nm (see ESI, Fig. S6–S9† for
the images showing where the measurements made for each
samples). Due to the agglomeration upon drying, the length
measurements should be interpreted with caution because it
was oen unclear where one non-spherical nanoparticle ended,
however, the larger widths of the PCL-CNTs nanocomposites
compared to the CNTs alone suggested that the PCL has
deposited on the surface of the CNTs. The SEM characterisation
data provides strong evidence that the process of combining the
PCL and CNTs in the same phase during the oil-in water
emulsion solvent evaporation method results in nanocomposite
rods that consist of CNTs coated in PCL.Table 1 Summary of the concentrations and compositions of the
samples of PCL nanoparticles, CNT dispersion and PCL-CNT nano-
composites prepared for further investigation
Sample
Concentrations used in
sample preparation
(mg mL1) Composition (%)
PCL CNTs SDS PCL CNTs
PCL 10 0 1.5 100 0
CNTs 0 0.9 1.5 0 100
PCL-CNTs 10 0.9 1.5 93 7
This journal is © The Royal Society of Chemistry 2018In order to providemore evidence for the preparation of PCL/
CNT nanocomposites AFM was utilised to characterise the
samples and measure the elastic modulus of all three samples
(AFM images are shown as insets in Fig. 5). Literature values for
the elastic modulus of PCL and CNT are 600 MPa62 and 1 TPa63
respectively. AFM nanomechanical analysis measures the
properties associated with 2 nm depth surface of material,59
therefore a modulus for approximately 600 MPa was expected in
the event of successful PCL-CNT nanocomposites. The Peak-
force quantitative nanoscale mechanical method relies on the
selection of an appropriate stiﬀness cantilever depending on
the expected elastic modulus of the sample. However, no probe
of an appropriate stiﬀness was available for the CNTs. Hence,
we conducted all the AFM experiments using the same probe.
The probe used in this experiment (TAP525) is recommended by
the manufacturer (Bruker) for samples with elastic modulus
values in the range 1–20 GPa. Therefore, it was not possible to
obtain reliable modulus values for the CNTs alone. However,
analysis of the DMT64 modulus for both the PCL and PCL-CNT
nanocomposite provide comparatively similar values of 770 and
560 MPa respectively, indicating that all the CNTs have been
coated with at least 2 nm of PCL. The moduli of both samples
were consistent across the surfaces, and no regions of very high
modulus were observed in the nanocomposite sample which
would have indicated uncoated CNTs (see ESI, Fig. S10†). While
the nanocomposites showed a similar surface modulus to that
of PCL, it is likely that high modulus of the CNT would mean
that the bulk modulus of the nanocomposites would be
comparable, this could be of particular interest for drug delivery
applications as it has previously been shown that materials with
higher moduli display greater cellular uptake.65 The brous
morphology observed for the PCL-CNT sample by SEM and the
stiﬀness as determined by AFM further supports the concept
that the CNTs have been coated with PCL to give high aspect
ratio nanocomposites. Thermo-gravimetric analysis (TGA) was
also used to provide information on the thermal stability and
CNT content of the PCL-CNT nanocomposites.36,41,66 The
decomposition behaviour of the CNTs and PCL nanoparticles
and PCL-CNT nanocomposites are shown in Fig. 6. The CNTs
were found to show thermal stability over the temperature range
tested, in agreement with the literature.67 Literature data on SDS
alone has previously shown to display a mass loss commencing
at 200 C until 300 C at which 73% of the mass of the
compound has been lost,67 while PCL has been shown to
degrade when heated above 360 C under inert atmosphere with
no residue mass remaining at 500 C.68 In the context of this
information, the start of degradation for the sample of PCL
nanoparticles stabilised by SDS began at approximately 210 C
which was likely due to the degradation of the SDS up to
approximately 300 C where the data exhibits a shoulder. This
TGA curve steepens abruptly at ca. 345 C that is likely associ-
ated with the start of the degradation of the PCL. Above 400 C
very little further mass loss was noted and the residue mass of
19.6% at 600 C was due to the SDS. For the PCL-CNT nano-
composite sample, the onset of themass loss was approximately
220 C which also corresponded to the degradation SDS within
the nanocomposite. The increase in the degradationRSC Adv., 2018, 8, 16444–16454 | 16449
Fig. 5 Analysis of the PCL, CNT and PCL-CNT (93% PCL, 7% CNTs bymass) nanocomposites by SEM and AFM (inset): (A) PCL alone, (B) CNTs and
(C) PCL-CNTs composites. The AFM images are based on the peak force error measurements. The AFM images were not obtained from the same
region shown in the SEM image, but have been inset so as to assist direct comparison with the morphologies revealed both techniques at the
same scale. The scale bar applies to both the SEM images and inset AFM images.
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View Article Onlinetemperature of the SDS could potentially suggest that the
formation of the nanocomposite structure has increased the
thermal stability of the SDS in the nanocomposite. A slight
shallowing of the TGA curve was observed at 290 C which may
be associated with completion of the SDS degradation. The
curves steepens again around 345 C, which may be associated
with the PCL beginning to degrade. This eﬀect was less
pronounced in the PCL-CNT nanocomposite compared to the
PCL nanoparticles which may be due to the presence of the CNT
in the nanocomposite altering the degradation behaviour of the
PCL.48 Above 400 C no further mass loss was seen for the
nanocomposite and the residue mass at 600 C was 29.2%. The
PCL-CNT nanocomposite showed a higher residue mass
compared to the PCL alone nanoparticles. This 9.6% of the
mass can be attributed to the CNTs present within PCL-CNT
nanocomposites, which matches a literature value of 10% for
PCL graed CNTs.48 This mass is higher than expected (theFig. 6 Analysis of the PCL-CNT (93% PCL, 7% CNTs by mass) nano-
composite and its constituents by TGA. The concentrations used
during preparation were 10 mg mL1 of PCL and 1.5 mg mL1 SDS for
PCL; 10 mg mL1 of PCL, 1.5 mg mL1 SDS and 0.9 mg mL1 CNTs for
PCL-CNTs. CNTs consists of 0.9 mg mL1 CNTs alone.
16450 | RSC Adv., 2018, 8, 16444–16454theoretical composition of the sample was 93% PCL, 7% CNTs
by mass) and may be attributed to a slight increase in the
concentration of the CNT dispersion due to some evaporative
loss of DCM during sonication prior to the emulsication.
Ramanmeasurements were also used to characterise PCL, CNTs
and PCL-CNTs particles. The presence of the peaks for both the
PCL and CNT indicates that the nanocomposite sample
contains both of PCL and CNT (see ESI, Fig. S11†).Fractionation of the particles by asymmetric ow eld ow
fractionation and measurements of hydrodynamic diameters
Next, the PCL alone and the PCL-CNT nanocomposite samples
were further analysed by asymmetric ow eld ow fraction-
ation with the aim of obtaining high resolution sizing of the
nanoparticles in the dispersed state. High resolution sizing
would make it possible to determine if the PCL/CNT nano-
composites consisted of a single population of particle rather
than resulted in two separate populations of PCL or CNTs alone.
Asymmetric ow eld ow fractionation separates samples
based on hydrodynamic diameter69 with smaller particles
eluting before larger particles, the fractionated sample then
passes through inline detectors to determine the diameter of
the particles. The separation conditions were chosen from
previous studies of CNTs.57 Fig. 7 shows the data for the
asymmetric ow eld ow fractionation analysis of the samples
combining the absorbance from UV-VIS detector and Z-average
diameter asmeasured by inline DLS. The UV-vis detector was set
to a wavelength of 300 nm, chosen based on absorbance spectra
of PCL and CNTs, and thus provides information on the
concentration of the particles. The samples showed good
separation and the absence of a void peak revealed that aggre-
gation has not occurred in the system. The sample that con-
sisted of PCL alone was found to consist of a higher dynamic
diameter distribution between 11 nm and 115 nm, with the
mode of the UV-vis measurement equating to a diameter ofThis journal is © The Royal Society of Chemistry 2018
Fig. 7 Fractogram of PCL and PCL-CNTs (93% PCL, 7% CNTs by mass)
obtained from asymmetric ﬂow ﬁeld ﬂow fractionation coupled online
with UV-VIS detector. Hydrodynamic diameters were obtained from
DLS coupled online.
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View Article Online93 nm. The size range of PCL-CNTs sample was between 11 nm
and 350 nm with the mode of the UV-vis measurement equating
to a diameter of 138 nm. A sample of CNT alone was also ana-
lysed but is not directly comparable to the PCL and nano-
composites, the uncoated CNT surface will likely have
a diﬀerent interaction with the membrane in the AF4 compared
to the other samples with the PCL coating which may have
resulted in diﬀerent elution behaviour. The CNTs alone con-
sisted of a distribution of 16 to 187 nm (see ESI, Fig. S12†) The
PCL-CNT nanocomposites were found to have larger hydrody-
namic diameters compared with pristine CNTs and PCL alone.
The measurements obtained from the detector coupled online
with asymmetric ow eld ow fractionator showed higher
intensity for PCL-CNTs compared to the PCL and CNT, which
was due to the higher concentration of composites in the
sample.
As previously stated, asymmetric ow eld ow fractionation
separates a sample based on the hydrodynamic diameter;
particles of the same diameter should elute at the same time.
However, as shown in Fig. 7, PCL or PCL-CNT nanocomposite
particles with the same hydrodynamic diameter eluted at
considerably diﬀerent times. The PCL-CNT nanocomposites
tended to elute before the PCL alone particles. Similar behav-
iour for non-spherical particles has been published by Gigault
et al. in which they showed that longer gold nanorods (GNRs)
with the same diameters eluted earlier than shorter GNRs.70 It
has been suggested that elution of non-spherical particles
depends on an aspect ratio and steric-entropy contribution
associated with their orientation. Gigault et al. suggested thatTable 2 Summary of the diameter and PdI for samples without and with
Unloaded
Z-average/
diameter nm PdI
PCL 90  1 0.160  0
CNTs 149  7 0.330  0
PCL-CNTs 215  8 0.330  0
This journal is © The Royal Society of Chemistry 2018GNRs located higher in the channel elute faster than associated
closer to the membrane.70 We believe that the earlier elution of
the PCL-CNT nanocomposites compared to the spherical PCL
alone nanoparticles was due to their higher aspect ratio of the
nanocomposites.Drug loading and release
Finally, the drug loading and release from PCL, CNTs and PCL-
CNTs nanocomposites was investigated. In this work docetaxel,
an eﬀective anticancer drug71–73 was used. Docetaxel (DCX) has
some clinical limitations associated with its poor water solu-
bility.74 The anticancer drug was encapsulated in the nano-
composite carriers, while PCL alone and CNTs alone were also
tested as controls. Drug encapsulation was achieved by
including DCX into the oil phase for the particle preparation.
The resulting DCX loaded samples were analysed by DLS (as an
unfractionated sample) to provide a mean diameter, PdI and
distribution plot. Table 2 shows the DLS results for PCL, CNT
and PCL-CNTs. The nanocomposites showed larger mean
diameters compared with PCL and pristine CNT. The DLS
distribution graph for the PCL alone sample was monomodal.
(See ESI, Fig. S13†). The CNTs and PCL-CNTs have a PdI of 0.33
which means that the distribution is broader than the PCL
alone particles, this is likely due to the polydisperse nature of
the CNTs themselves which gave a PdI value of 0.33. Hydrody-
namic diameter and PdI of the three samples were also
measured aer encapsulation of DCX. The size and PdI of CNTs
alone were higher compared with unloaded CNTs alone. These
results potentially indicate that molecules of anti-cancer drug
adsorbed to the surface of the CNTs may have possibly resulted
in some aggregation of the CNTs. The properties of CNTs have
previously shown that loading via p–p stacking is possible for
DCX.75 It was found that aer encapsulation, PCL and PCL-
CNTs showed a lower diameter and PdI. In this case it is
possible another type of interaction between the PCL/CNTs and
DCX may have altered the size of the PCL–DCX nanoparticles
and PCL-CNTs-DCX nanocomposites. The entrapment eﬃ-
ciency (EE) was also analysed by HPLC (EECNT ¼ 95%, EEPCL ¼
81% and EEPCL-CNT ¼ 89%).
In vitro release experiments were then conducted to observe
the drug release behaviour of the nanocomposites. The drug
released over time is presented in Fig. 8. The nanocomposites
and CNT alone encapsulated more anti-cancer drug compared
with PCL alone. The release of DCX from diﬀerent systems has
been studied previously.76,77 In those studies, the authors
showed that pH, temperature, solvent and type of carrier haveencapsulated DCX obtained from DLS
Loaded DCX
Z-average/diameter
nm PdI
.008 73  6 0.180  0.009
.007 314  10 0.530  0.034
.013 162  5 0.400  0.019
RSC Adv., 2018, 8, 16444–16454 | 16451
Fig. 8 The graph presents docetaxel releasing study (% of drug
released vs. time) for CNTs, PCL and PCL-CNTs (93% PCL, 7% CNTs by
mass) obtained from HPLC analysis. The data showed three diﬀerent
proﬁles for releasing anti-cancer drug.
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View Article Onlinean eﬀect on drug release. Our release data showed that DCX is
released most rapidly from the PCL-CNTs. The slowest prole
was found with the CNTs alone with 31% of the drug released in
96 hours matching the DCX release behaviour from CNTs
previously shown in the literature.78,79 The diﬀerence in the
release proles between the CNTs and the PCL-CNT nano-
composites may be due to the diﬀerent structures of the
nanocarriers. In the case of the PCL-CNT nanocomposites, the
PCL coating the surface may have disrupted the ability for the
DCX to adsorb onto the CNT. This is supported by the literature
in which it is stated that drug release behaviours from CNTs are
altered when diﬀerent polymer surface functionalisations are
present.78 No degradation of the drug was detected aer the
drug release from all of the samples (examples of the chro-
matograms obtained from HPLC analysis are shown in the ESI,
Fig. S14–S17†). These ndings show that not only can the PCL-
CNT successfully encapsulate DCX but also has the ability to
release it. More interestingly, the diﬀerence in the release
behaviour of DCX from the diﬀerent samples suggests that
there is a potential to tune the release prole by varying the
composition of the nanocomposites.Conclusions
In the present study, PCL-CNT nanocomposites were prepared
by a facile oil-in water emulsion solvent evaporation method.
This approach produced rod-like, non-spherical nanoparticles.
Diﬀerent sizes and morphologies of nanoparticles were
produced depending on the concentration of SDS, CNTs and
PCL. The samples with rod-like morphologies and the lowest
diameter and PdI were synthesised using 1.5 mg mL1 of SDS,
0.9 mg mL1 of CNTs and 10 mg mL1 PCL. The AFM analysis
revealed that the incorporation of the CNTs in the nano-
composites did not increase the modulus of the particles,
including the successful surface coverage of the CNTs with PCL.
In addition, TGA analysis of the PCL-CNT nanocomposite also
showed that they contained 9.6% CNTs by mass. Asymmetric
ow eld ow fractionation measurements showed good sepa-
ration of particles and the PCL-CNTs had higher hydrodynamic16452 | RSC Adv., 2018, 8, 16444–16454diameters than PCL and CNTs alone. Raman data indicated the
presence of both PCL and CNTs in the nanocomposites. DCX
loading in PCL, CNTs and PCL-CNTs were determined by HPLC
and showed high entrapment eﬃciencies (CNT ¼ 95%, PCL ¼
81% and PCL-CNT ¼ 89%). Moreover, faster release of DCX
from PCL-CNTs was observed with about 90% of the drug
released from the nanocarriers aer approximately 100 h.
To the best of our knowledge this is the rst example of
producing high-aspect ratio PCL-CNT nanocomposites using
a simple oil-in water emulsion solvent evaporation method. The
high entrapment eﬃciencies of the nanocomposites oﬀer the
potential for these nanocomposites to be used in drug delivery
applications. We hypothesise that the needle-like morphology
and high modulus of the nanocomposites will enhance the
cellular uptake of anticancer drugs and the coating with PCL
will potentially reduce any cytotoxicity associated with the
pristine CNTs.
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